A Phase 2 interventional study of FX006 32 mg and TAcs 40 mg in Bilateral Knee Osteoarthritis, sponsored by Pacira Pharmaceuticals, Inc. Completed at 3 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing FX006 in Osteoarthritis — none open to participants now, none under way, none of them phase 3. FX006 · Osteoarthritis.
Among the 15 studies testing FX006 in Osteoarthritis, this one is the 11th largest by enrollment, is one of 3 that started in 2017, is one of 11 in phase 2, and was the 11th registered.
2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →None of the 15 studies testing FX006 in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →
FX006: first FDA approval 1957 (ARISTOCORT). What it is approved for, and how studies give it, is on its page →
Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.
Median enrollment 55 across the 15 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 1 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 17 (63%) have results posted.
20 studies in Osteoarthritis by Pacira BioSciences, Inc.: 1 open now, 2 under way, 1 of them phase 3. Of 18 finished, 16 (89%) have results posted.
Among the 20 studies in Osteoarthritis by Pacira BioSciences, Inc., this one is the 16th largest by enrollment, is one of 3 that started in 2017, is one of 12 in phase 2, and was the 13th registered.
Pacira BioSciences, Inc.’s Osteoarthritis studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing FX006 in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pacira BioSciences, Inc.’s 20 in Osteoarthritis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, parallel group study to compare systemic exposure of triamcinolone acetonide following administration into both knees of either FX006 or TAcs.
This is a randomized, open label, parallel group study that will be conducted in male and female patients ≥ 40 years of age with bilateral knee OA.
Approximately 24 patients will be randomized to one of two treatment groups (1:1) and treated with IA injections to both knees of either:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
Drug: FX006 32 mg
Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
Drug: TAcs 40 mg
Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
Also known as: Zilretta
Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
Also known as: Kenalog®-40 Injection, Triamcinolone Acetonide Crystalline Suspension (TAcs), TCA-IR 40
Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma
Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma. For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations
Time frame: 43 days
Incidence of Treatment Emergent Adverse Events
Safety analyses were conducted using the safety population. Analyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).
Time frame: 43 days
| Milestone | FX006 32 mg | TAcs IR 40 mg |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma. For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations
| pg/mL | FX006 32 mg | TAcs 40 mg |
|---|---|---|
| Day 1- Hour 1 | 1801.5 (1261.50 to 2572.77) | 4507.9 (1205.43 to 16857.74) |
| Day 1 - Hour 2 | 1893.6 (1328.58 to 2698.84) | 5140.1 (1327.67 to 19899.79) |
| Day 1 - Hour 3 | 1958.1 (1336.54 to 2868.86) | 5443.8 (1357.81 to 21825.90) |
| Day 1 - Hour 4 | 2013.8 (1381.39 to 2935.59) | 5454.2 (1409.98 to 21098.36) |
| Day 1 - Hour 5 | 1914.4 (1291.93 to 2836.82) | 5338.9 (1366.93 to 20852.59) |
| Day 1 - Hour 6 | 1900.2 (1293.77 to 2790.96) | 5430.6 (1442.24 to 20448.57) |
| Day 1 - Hour 8 | 1928.1 (1288.45 to 2885.17) | 5199.0 (1418.52 to 19054.80) |
| Day 1 - Hour 10 | 1839.8 (1241.72 to 2725.96) | 4948.8 (1392.07 to 17593.31) |
| Day 1 - Hour 12 | 1793.9 (1247.06 to 2580.66) | 4507.8 (1294.51 to 15697.14) |
| Day 2 - Hour 24 | 1948.8 (1349.93 to 2813.36) | 4185.4 (1614.39 to 10850.75) |
| Day 8 | 1397.0 (1073.13 to 1818.65) | 450.8 (230.66 to 880.92) |
| Day 15 | 956.2 (759.23 to 1204.25) | 428.7 (231.92 to 792.29) |
| Day 29 | 445.8 (313.12 to 634.80) | 334.6 (182.45 to 613.80) |
| Day 43 | 265.8 (199.56 to 354.03) | 241.0 (119.11 to 487.54) |
Safety analyses were conducted using the safety population. Analyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).
| participants | FX006 32 mg | TAcs 40 mg |
|---|---|---|
| Patients with TEAE Grade 1 | 6 | 3 |
| Patients with TEAE Grade 2 | 1 | 2 |
| Patients with TEAE Grade 3 | 1 | 0 |
| Patients with TEAE Grade 4 | 0 | 0 |
| Patients with TEAE Grade 5 | 0 | 0 |
Collected over Adverse Events were collected following IA administration through the final study visit at 43 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FX006 32 mg | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| TAcs 40 mg | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Event | FX006 32 mg | TAcs 40 mg |
|---|---|---|
| BronchitisInfections and infestations | 2/12 | 0/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 2/12 |
| HaemorrhoidsGastrointestinal disorders | 0/12 | 1/12 |
| VomitingGastrointestinal disorders | 1/12 | 0/12 |
| FatigueGeneral disorders | 0/12 | 1/12 |
| Injection Site PainGeneral disorders | 1/12 | 0/12 |
| Vessel Puncture Site HaematomaGeneral disorders | 1/12 | 0/12 |
| Food AllergyImmune system disorders | 0/12 | 1/12 |
| NasopharyngitisInfections and infestations | 1/12 | 0/12 |
| SinusitisInfections and infestations | 0/12 | 1/12 |
| Age, Continuous(years) | FX006 64 mg | TAcs IR 80mg | Total |
|---|---|---|---|
| Mean | 61.8 ± 6.45 | 61.6 ± 8.17 | 61.7 ± 7.20 |
| Sex: Female, Male(Participants) | FX006 64 mg | TAcs IR 80mg | Total |
|---|---|---|---|
| Female | 10 | 9 | 19 |
| Male | 2 | 3 | 5 |
| Ethnicity (NIH/OMB)(Participants) | FX006 64 mg | TAcs IR 80mg | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 10 | 12 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FX006 64 mg | TAcs IR 80mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 10 | 10 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | FX006 64 mg | TAcs IR 80mg | Total |
|---|---|---|---|
| Mean | 33.31 ± 3.669 | 30.35 ± 4.955 | 31.83 ± 4.524 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Mar 2018, 3 months.
Results were first posted in May 2019, 1 year 1 month after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 3 months is below that.
Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FX006